An interventional study of Attention bias modification treatment (ABMT) and Attention Control Condition in Anxiety Disorders, sponsored by Yair Bar-Haim. Status unknown at 1 site in Israel. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-09-18.
Sponsored by Yair Bar-Haim · Not applicable, Interventional, and Treatment
First-line psychosocial treatments for anxiety disorders in children are largely exposure-based cognitive behavioral therapies (CBTs). Despite strong evidence supporting CBT's efficacy, for up to 50% of youth patients, symptoms of anxiety persist after a full course of treatment. What are the treatment options for these youth? Unfortunately, there is not a single empirical study in the youth anxiety treatment literature that has systematically examined treatment augmentation for youth who fail to respond to CBT. Empirical efforts to address this issue are important because youth who do not respond to CBT continue to suffer emotional distress and impairment associated with anxiety disorders. This study will address this gap via double-blind randomized controlled trial of Attention Bias Modification Treatment (ABMT) for anxious 10-18 year-olds who did not respond to standard CBT. Attention biases in threat processing have been assigned a prominent role in the etiology and maintenance of anxiety disorders. ABMT utilizes computer-based protocols to implicitly modify biased attentional patterns in anxious patients. Here, participants will be CBT non-responders who will be assessed by using clinical interviews and parent- and self-rated questionnaires before and after eight sessions of ABMT or placebo control, and again at an eight-week follow-up. We expect to see reduction in anxiety symptoms in the Attention Bias Modification Treatment (ABMT) group relative to the placebo control group. We also expect the findings to inform pathways to treatments for anxious children who do not respond to current standard first-line therapy, and to provide initial information on mechanisms of ABMT efficacy.
4,874 studies on the registry are indexed under Anxiety Disorders; 1,394 are open to participants now.
This study's planned enrollment of 100 is above the median of 80 across 4,180 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →Yair Bar-Haim is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
To be included all youth must:
Exclusion Criteria: To be excluded youth must:
Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
Behavioral: Attention bias modification treatment (ABMT)
Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
Behavioral: Attention Control Condition
Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
The Pediatric Anxiety Rating Scale (PARS)
The PARS assesses global anxiety severity across different anxiety disorders in youth.
Time frame: expected average time frame of 6 weeks.
Anxiety Related Emotional Disorders - Child/Parent Version (SCARED-C/P)
The SCARED is a 41-item self and parent-report instrument designed to assess anxiety in children and adolescents. Screen for Child
Time frame: expected average time frame of 6 weeks.
This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yair Bar-Haim